华熙生物科技股份有限公司 2023 年半年度募集资金存放与实际使用情况 的专项报告 证券代码：688363 证券简称：华熙生物 公告编号：2023-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 (一) 实际募集资金金额、资金到位时间 经中国证券监督管理委员会证监许可（2019）1796 号《关于同意华熙生物科 技股份有限公司首次公开发行股票注册的批复》，并经上海证券交易所同意，本 公司由主承销商华泰联合证券有限责任公司通过上海证券交易所系统，采用向战 略投资者定向配售、网下向符合条件的投资者询价配售和网上向持有上海市场非 限售 A 股股份或非限售存托凭证市值的社会公众投资者定价发行相结合的方式 公开发行人民币普通股（A 股）49,562,556 股，每股面值 1 元，发行价为 47.79 元/股，增加股本 49,562,556 股。 本公司募集资金总额为 2,368,594,551.24 元，扣除承销费、保荐费人民币 92,660,000.00 元 ， 本公 司 于 2019 年 10 月 ...

华熙生物科技股份有限公司（以下简称"公司"或"华熙生物"）于 2023 年 8 月 29 日召开第二届董事会第八次会议及第二届监事会第七次会议，分别审 议通过了《关于调整部分募投项目实施进度的议案》，同意华熙生物生命健康产 业园项目（以下简称"健康产业园项目"）实施进度调整至 2024 年第 2 季度达 到预定可使用状态。 一、募集资金基本情况 证券代码：688363 证券简称：华熙生物 公告编号：2023-023 华熙生物科技股份有限公司 关于调整部分募投项目实施进度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 经 2019 年第一次临时股东大会审议通过，公司申请首次公开发行人民币普 通股股票（A 股）并在科创板上市，拟发行不超过 49,562,556 股，每股面值人民 币 1 元。经中国证券监督管理委员会证监许可（2019）1796 号文核准，同意本 公司向社会公众发行人民币普通股（A 股）不超过 49,562,556 股。本公司实际向 社会公众发行人民币普通股（A 股）49,562,556 股，发行价为 4 ...

华泰联合证券有限责任公司关于华熙生物科技股份有限公司 调整部分募集资金投资项目实施进度的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为 华熙生物科技股份有限公司（以下简称"华熙生物"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《上海证券交易所科创板股票上市规则》、 《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》、《科创板上市公司持续监管办法（试行）》等法律法规，对华熙生物调 整华熙生物生命健康产业园项目（以下简称"健康产业园项目"）实施进度事项 进行了认真、审慎的核查，核查情况如下： 一、募集资金基本情况 公司首次公开发行人民币普通股 49,562,556 股，发行价格为 47.79 元/股，募 集资金总额为人民币 236,859.46 万元，扣除发行费用合计人民币 11,964.01 万元 （不含增值税）后，实际募集资金净额为人民币 224,895.44 万元。上述资金已于 2019 年 10 月 30 日全部到位，致同会计师事务所（特殊普通合伙）已于 2019 年 10 月 30 日出具了致同验字（2019）第 11 ...

华熙生物科技股份有限公司 独立董事关于公司第二届董事会第八次会议相关议案的 独立意见 根据《公司法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》《公司章程》《独立董事工作制度》的有关规定，我们作为华熙生物科技股 份有限公司（以下简称"公司"）的独立董事，本着对公司及全体股东负责的态度， 按照实事求是的原则，基于独立判断的立场，针对第二届董事会第八次会议相关议 案，发表如下独立意见： 1. 《关于调整部分募投项目实施进度的议案》 本次部分募投项目实施进度的调整，为公司根据该项目实际实施进展，经审慎 论证后作出，已经公司董事会审议通过，表决程序合法有效，符合《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求》及《上海证券交易所 科创板上市公司自律监管指引第 1 号——规范运作》的相关规定，不涉及募投项 目的变更，不存在变相改变募集资金用途和损害股东利益、特别是中小股东利益的 情况。我们同意调整部分募投项目实施进度事项。 2. 《关于 2023 年半年度募集资金存放与实际使用情况的议案》 公司 2023 年半年度募集资金存放与实际使用情况符合《上市公司监管指引第 2 号— ...

二、 提议的内容 1、回购股份的种类：公司发行的人民币普通股（A 股） 2、回购股份的用途：用于员工持股计划或者股权激励。若公司未能在股份 回购实施结果暨股份变动公告日后 3 年内使用完毕已回购股份，尚未使 用的已回购股份将予以注销。如国家对相关政策作出调整，则回购方案 按调整后的政策实行。 三、 提议人在提议前 6 个月内买卖本公司股份的情况 证券代码：688363 证券简称：华熙生物 公告编号：2023-022 华熙生物科技股份有限公司 关于收到实际控制人、董事长兼总经理提议回购 公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日收到 公司实际控制人、董事长兼总经理赵燕女士（以下简称"提议人"）《关于提议华 熙生物科技股份有限公司回购公司股份的函》，具体内容如下： 一、 提议人提议回购股份的原因和目的 提议人基于对公司未来高质量可持续发展的信心和对公司内在价值的认可， 为维护广大投资者利益，增强投资者对公司的投资信心，同时为促 ...

Financial Performance - The total revenue for Q1 2023 was RMB 1,305,155,874.23, representing a year-over-year increase of 4.01%[4] - The net profit attributable to shareholders was RMB 200,485,364.45, with a slight increase of 0.37% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was RMB 150,990,458.74, showing a decrease of 17.44% year-over-year[4] - The company reported a total profit for Q1 2023 of RMB 241,748,595.19, slightly down from RMB 242,002,411.76 in Q1 2022, reflecting a marginal decline[16] - Net profit for Q1 2023 reached RMB 200,972,272.94, compared to RMB 197,645,537.46 in Q1 2022, indicating a growth of 1.2%[16] Cash Flow - The cash flow from operating activities was negative at RMB -198,334,371.86, indicating a significant cash outflow[4] - Cash flow from operating activities for Q1 2023 was a net outflow of RMB 198,334,371.86, an improvement from a net outflow of RMB 217,169,901.68 in Q1 2022[18] - The net cash inflow from investment activities was CNY 74,979,759.68, a decrease from CNY 181,874,757.66 in the previous quarter[19] - The net cash outflow from financing activities was CNY -14,003,290.72, a significant decline from CNY 34,990,094.04 in the previous quarter[19] - Cash flow from operating activities showed a net decrease of CNY 136,889,923.79 compared to a decrease of CNY 5,611,236.68 in the previous quarter[19] Assets and Liabilities - The total assets at the end of the reporting period were RMB 8,459,569,793.72, down 2.56% from the end of the previous year[5] - The company's current assets totaled ¥3,546,740,658.59, down from ¥4,023,100,101.48, indicating a decrease of about 11.83%[11] - Total liabilities decreased to ¥1,520,132,931.90 from ¥1,998,766,272.32, representing a reduction of about 23.97%[13] - The company's equity increased to ¥6,939,436,861.82 from ¥6,682,988,078.25, reflecting an increase of approximately 3.84%[13] Research and Development - Research and development expenses totaled RMB 83,153,130.85, accounting for 6.37% of total revenue, a decrease of 0.12 percentage points from the previous year[5] - Research and development expenses for Q1 2023 amounted to RMB 83,153,130.85, slightly up from RMB 81,481,354.61 in Q1 2022, reflecting a focus on innovation[15] Earnings Per Share - The basic and diluted earnings per share were both RMB 0.42, unchanged from the previous year[5] - The company reported a basic earnings per share of RMB 0.42 for both Q1 2023 and Q1 2022, showing stability in earnings per share[17] Other Income and Expenses - Non-recurring gains totaled RMB 49,494,905.71, primarily from government subsidies and other non-operating income[7] - The company recorded other income of RMB 59,285,971.49 in Q1 2023, significantly higher than RMB 17,523,083.33 in Q1 2022, indicating improved ancillary revenue streams[15] - The company reported a tax expense of RMB 40,776,322.25 for Q1 2023, down from RMB 44,356,874.30 in Q1 2022, indicating a reduction in tax liabilities[16]

证券代码：688363 证券简称：华熙生物 公告编号：2023-014 华熙生物科技股份有限公司（以下简称"公司"）已于 2023 年 03 月 31 日发 布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经 营成果、财务状况，公司计划于 2023 年 04 月 26 日下午 15:00-16:30 举行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以视频结合网络互动方式召开，公司将针对 2022 年度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 会议召开时间：2023 年 04 月 26 日(星期三) 下午 15:00-16:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频和网络文字互动 投资者可于 2023 年 04 月 19 日(星期三)至 04 月 25 日(星期二)16:00 前登录 上 证 路 演 中 心 网 ...

Financial Performance - In 2022, the company achieved a net profit attributable to shareholders of CNY 970,918,593.78, with a parent company net profit of CNY 921,309,132.56[5] - The proposed cash dividend for 2022 is CNY 6.1 per 10 shares, totaling CNY 293,462,018.97, which represents 30.23% of the net profit attributable to shareholders[5] - The company's operating revenue for 2022 reached RMB 6,359,191,975.49, representing a year-on-year increase of 28.53% compared to RMB 4,947,773,755.75 in 2021[20] - The net profit attributable to shareholders of the listed company was RMB 970,918,593.78, up 24.11% from RMB 782,334,573.48 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 852,144,424.61, reflecting a growth of 28.46% year-on-year[20] - The basic earnings per share for 2022 were RMB 2.02, an increase of 23.93% from RMB 1.63 in 2021[21] - The overall gross margin for the reporting period was 76.99%, indicating a slight decrease of 1.07 percentage points[178] Audit and Compliance - The company has received a standard unqualified audit report from its accounting firm[5] - The board of directors has confirmed the accuracy and completeness of the annual report[4] - The company has not violated any decision-making procedures regarding external guarantees[7] - The company has confirmed that all directors were present at the board meeting[5] Risks and Challenges - The company reported no significant risks that could materially affect its operations during the reporting period[4] - The company faces risks related to new product development, including potential failures due to high costs or slow progress[160] - The company has a risk of core technology personnel turnover, which could adversely affect its competitive edge and operational stability[162] - The company is exposed to risks related to new product market promotion and management of distributors, which could impact sales and brand reputation[164] Research and Development - R&D investment reached CNY 388 million, a year-on-year increase of 36.52%, with 827 R&D personnel, an increase of 256[46] - The number of ongoing projects increased to 337, up by 98, and the company applied for 719 patents, an increase of 194[46] - The company has established a comprehensive platform for synthetic biology, integrating talent, technology, and transformation processes[51] - The company is focusing on the application of key technologies in the controlled synthesis and modification of hyaluronic acid, aiming to establish a green health industry park[108] - The company has developed a patented method for large-scale production of low molecular weight hyaluronic acid, achieving a molecular weight range from 2kDa to 4,000kDa[91] Product Development and Innovation - The company has developed a diverse range of products extending from sodium hyaluronate raw materials to various bioactive substances, medical terminal products, functional skincare products, and functional foods[98] - The company launched 5 new products in the "Night Cap" series to meet the needs of night owls, utilizing online channels for rapid promotion[44] - The company has introduced functional food products, including the "Water Skin Spring" and "Black Zero" brands, targeting health trends in the food market[68] - The company is focusing on expanding its product line with new formulations aimed at skin barrier repair and anti-aging[104] - The company has successfully developed its own proprietary recombinant collagen using a synthetic biology platform, expanding its diverse product matrix of biological materials[95] Market and Sales - The company is the world's largest producer and seller of hyaluronic acid, with a market share of 44% in 2021[89] - The company has expanded its market presence in over 70 countries and regions, with a focus on localizing operations in key markets[157] - The company’s food-grade hyaluronic acid has seen the fastest growth in sales globally, with significant exports to Japan, South Korea, the United States, the European Union, and Australia[76] - The company’s medical products are sold through a combination of distribution and direct sales, with agreements established with distributors regarding pricing and settlement methods[70] Supply Chain and Operations - The company has a strict supplier management system, conducting annual evaluations of qualified suppliers to ensure the safety stock of materials and timely delivery, which is crucial for maintaining cost and quality[69] - The company primarily adopts a sales-driven production model, preparing safety stock based on market forecasts, with most products produced in-house and some skincare and food products outsourced[69] - The company’s production processes adhere to strict GMP and ISO standards, ensuring product quality and safety across various product lines[69] Corporate Social Responsibility - The company has donated over 10 million yuan worth of epidemic prevention and living materials to support public health efforts[58] - The company is exploring sustainable development paths in the health industry, focusing on high quality and efficiency[159] Future Outlook - The company has outlined its future plans and development strategies, which are subject to investment risks[6] - The company aims to enhance its competitive edge through continuous innovation and expansion in the medical device industry, targeting a revenue growth of over 200% in the next fiscal year[135]

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,384,920,970.33, representing a year-on-year increase of 28.76%[4] - The net profit attributable to shareholders for Q3 2022 was ¥204,214,799.15, with a year-on-year growth of 4.86%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥188,089,893.17, reflecting a year-on-year increase of 33.64%[4] - Total operating revenue for the first three quarters of 2022 reached ¥4,320,373,169.13, a significant increase from ¥3,012,233,218.80 in the same period of 2021, representing a growth of approximately 43.4%[20] - The net profit for Q3 2022 was CNY 667,158,735.38, an increase of 20.5% compared to CNY 553,856,001.46 in Q3 2021[21] - The total profit for Q3 2022 reached CNY 819,385,175.64, up from CNY 644,959,680.13 in the same period last year, reflecting a growth of 27.1%[21] - The operating profit for Q3 2022 was CNY 822,533,907.78, compared to CNY 647,351,111.06 in Q3 2021, indicating a rise of 27.0%[21] - The company reported a net profit margin improvement, with net profit for the first three quarters of 2022 showing a positive trend compared to the previous year, although specific figures were not disclosed[20] Research and Development - The total R&D investment for Q3 2022 was ¥97,807,572.45, which is a 14.66% increase compared to the same period last year[5] - The R&D investment accounted for 7.06% of operating revenue in Q3 2022, a decrease of 0.87 percentage points year-on-year[5] - Research and development expenses amounted to ¥277,266,180.12 in the first three quarters of 2022, up from ¥192,166,033.22 in the same period of 2021, reflecting a growth of approximately 44.4%[20] - The company emphasized the importance of R&D, with a notable increase in the number of projects and average salaries for R&D personnel, leading to a significant rise in R&D expenses[9] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥116,486,908.60, showing a significant decrease of 79.67% compared to the previous year[5] - The cash flow from operating activities for Q3 2022 was CNY 116,486,908.60, down from CNY 573,039,029.27 in Q3 2021, showing a decrease of 79.7%[23] - The cash and cash equivalents at the end of Q3 2022 were CNY 748,006,237.01, down from CNY 1,191,157,813.73 at the end of Q3 2021, a decrease of 37.2%[24] - The company's total assets at the end of Q3 2022 were ¥7,906,331,888.04, an increase of 5.37% from the end of the previous year[5] - Cash and cash equivalents increased significantly, with current assets totaling ¥3,670,449,848.51 compared to ¥3,984,152,562.74 in the previous year, reflecting a decrease of approximately 7.9%[20] Shareholder Information - The top shareholder, Huaxi Xinyu Investment Co., Ltd., holds 283,500,000 shares, representing 58.93% of total shares[11] - The second-largest shareholder, Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, holds 34,433,286 shares, accounting for 7.16%[11] - The company reported a total of 31,833 common shareholders at the end of the reporting period[11] Future Outlook and Strategic Focus - The company plans to expand its market presence and invest in new product development, focusing on innovative technologies to drive future growth[20] - The company has indicated a strategic focus on mergers and acquisitions to enhance its competitive position in the market[20] - The company has not disclosed any significant new product developments or technological advancements during the reporting period[14] - There is no indication of any mergers or acquisitions being pursued by the company in the near future[14] - The company has not provided specific future guidance or performance outlook in the current report[14] Inventory and Receivables - The company's inventory increased to ¥1,077,528,058.09 from ¥709,132,554.50 year-over-year, indicating a growth of approximately 51.8%[15] - Accounts receivable rose to ¥458,519,596.95, compared to ¥396,636,054.72 in the previous year, reflecting an increase of about 15.6%[15] Liabilities and Equity - Total liabilities decreased to ¥1,612,401,591.49 in the third quarter of 2022 from ¥1,801,280,273.07 in the same quarter of 2021, showing a reduction of approximately 10.5%[18] - The equity attributable to shareholders at the end of Q3 2022 was ¥6,298,139,115.63, reflecting a year-on-year increase of 10.51%[5] - The company's equity attributable to shareholders reached ¥6,298,139,115.63, up from ¥5,699,012,395.15 in the previous year, indicating an increase of about 10.5%[18]